Leukaemia (chronic myeloid) - nilotinib (discontinued) [ID79]
In development [GID-TAG408] Expected publication date: 01 May 2011
Search results
661 results
-
-
Atrial fibrillation - ximelagatran [ID376]
In development [GID-TAG377] Expected publication date: TBC
-
Clinically isolated syndrome - beta interferons and glatiramer acetate [ID109]
In development [GID-TAG415] Expected publication date: TBC
-
PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502
In development [GID-TA10402] Expected publication date: TBC
-
Nintedanib for untreated malignant pleural mesothelioma (ID1424)
In development [GID-TA10359] Expected publication date: TBC
-
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency ID1498
In development [GID-TA10420] Expected publication date: 23 June 2021
-
Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]
Proposed [GID-HST10034] Expected publication date: TBC
-
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]
Proposed [GID-TA10599] Expected publication date: TBC
-
Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]
Proposed [GID-TA10604] Expected publication date: TBC
-
Velmanase alfa for treating alpha-mannosidosis [ID800]
In development [GID-HST10010] Expected publication date: TBC
-
Pembrolizumab for previously treated endometrial cancer [ID1205]
In development [GID-TA10243] Expected publication date: TBC
-
Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289
In development [GID-TA10210] Expected publication date: TBC
-
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
In development [GID-TA10326] Expected publication date: TBC
-
Dabrafenib with trametinib for treating advanced, metastatic BRAF V600E mutation-positive non-small-cell lung cancer [ID929]
In development [GID-TA10121] Expected publication date: TBC
-
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
In development [GID-TA10405] Expected publication date: TBC
-
Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]
In development [GID-TA10252] Expected publication date: TBC
-
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]
In development [GID-TA10473] Expected publication date: TBC
-
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]
In development [GID-TA10223] Expected publication date: TBC
-
Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]
In development [GID-TA10465] Expected publication date: TBC
-
Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural mesothelioma [ID1575]
In development [GID-TA10486] Expected publication date: TBC
-
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck ID1355
In development [GID-TA10321] Expected publication date: TBC
-
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]
In development [GID-TA10483] Expected publication date: TBC
-
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565
In development [GID-TA10502] Expected publication date: TBC
-
Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466
In development [GID-TA10355] Expected publication date: TBC
-
Nintedanib for previously treated metastatic colorectal cancer [ID1030]
In development [GID-TA10138] Expected publication date: TBC
-
Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]
In development [GID-TA10140] Expected publication date: TBC
-
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]
In development [GID-TA10144] Expected publication date: TBC
-
NGR-TNF for previously treated advanced malignant pleural mesothelioma (ID655)
In development [GID-TA10183] Expected publication date: TBC
-
Nivolumab for treating recurrent glioblastoma [ID998]
In development [GID-TA10126] Expected publication date: TBC
-
Multiple sclerosis (primary-progressive) - fingolimod [ID62]
In development [GID-TAG221] Expected publication date: TBC
-
Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099]
In development [GID-TA10688] Expected publication date: TBC
-
The Assurance Nasal Alar SpO2 Sensor (discontinued)
In development [GID-MT510] Expected publication date: TBC
-
NBTXR-3 for treating soft tissue sarcoma [ID1050]
In development [GID-TA10226] Expected publication date: TBC
-
L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]
In development [GID-TA10452] Expected publication date: TBC
-
The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)
In development [GID-MT517] Expected publication date: TBC
-
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]
In development [GID-TA10248] Expected publication date: TBC
-
Nivolumab monotherapy for non-small-cell lung cancer [ID1088]
In development [GID-TA10148] Expected publication date: TBC
-
Nivolumab with radiation therapy for untreated glioblastoma ID1562
In development [GID-TA10443] Expected publication date: TBC
-
Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer (ID1135)
In development [GID-TA10233] Expected publication date: TBC
-
Brentuximab vedotin for untreated advanced Hodgkin lymphoma [1258]
In development [GID-TA10224] Expected publication date: TBC
-
Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma ID1470
In development [GID-TA10354] Expected publication date: TBC
-
Crizotinib for treating metastatic c-MET exon 14-positive non-small-cell lung cancer [ID1472]
In development [GID-TA10625] Expected publication date: TBC
-
Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]
In development [GID-TA10447] Expected publication date: TBC
-
Eculizumab for treating refractory myasthenia gravis [ID1064]
In development [GID-TA10176] Expected publication date: TBC
-
Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]
In development [GID-TA10628] Expected publication date: TBC
-
Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]
In development [GID-TA10627] Expected publication date: TBC
-
Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413
In development [GID-TA10329] Expected publication date: TBC
-
Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178
In development [GID-TA10199] Expected publication date: TBC
-
Ranibizumab for treating diabetic retinopathy [ID1592]
In development [GID-TA10521] Expected publication date: TBC
-
Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]
In development [GID-TA10277] Expected publication date: TBC